Table 2 Summary of linear mixed effect model analyses of bone outcomes

HAZ BMC

HAZ aBMD

Group

-0.47

(-0.91 to -0.03)

0.04*

-0.58

(-1.10 to -0.07)

0.03*

Sex

-0.51

(-0.98 to -0.04)

0.04*

-0.54

(-1.08 to 0.01)

0.06

MO (years)

0.04

(-0.15 to 0.07)

0.47

0.03

(-0.09 to 0.16)

0.59

HAZ BMC

HAZ aBMD

Group

-0.55

(-1.02 to -0.08)

0.03*

-0.69

(-1.24 to -0.14)

0.02*

Sex

-0.52

(-0.99 to -0.05)

0.03*

-0.55

(-1.10 to -0.01)

0.047*

MO

-0.07

(-0.20 to 0.06)

0.28

-0.01

(-0.16 to 0.14)

0.93

MVPA (minutes/day)

-3.55*10^− 3

(-0.01 to 0.00)

0.39

-0.01

(-0.01 to 0.01)

0.32

HAZ BMC

HAZ aBMD

Group

-0.45

(-0.83 to -0.06)

0.02*

-0.57

(-1.05 to -0.08)

0.03*

Sex

-1.29

(-1.88 to -0.70)

< 0.001*

-1.13

(-1.88 to -0.39)

0.004*

MO

-0.26

(-0.41 to -0.11)

0.001*

-0.13

(-0.32 to 0.06)

0.18

Lean mass (kg)

0.06

(0.03 to 0.10)

< 0.001*

0.05

(0.01 to 0.09)

0.03*

HAZ BMC

HAZ aBMD

Group

-0.45

(-0.88 to -0.02)

0.04*

-0.55

(-1.04 to -0.07)

0.03*

Sex

-0.61

(-1.07 to -0.14)

0.01*

-0.67

(-1.21 to -0.14)

0.02*

MO

-0.05

(-0.15 to 0.06)

0.38

0.02

(-0.10 to 0.15)

0.70

TSLH (% leg length)

2.24*10^− 3

(-0.00 to 0.00)

0.09

0.00

(0.00 to 0.01)

0.04*